Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trophos, a pharmaceutical company, has commenced phase II proof-of-concept study to assess the efficacy and safety of TRO40303, a mitochondria pore modulator, used in the treatment of cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI).
Subscribe to our email newsletter
TRO40303 causes prevention of stress-induced mitochondrial permeability transition, a target implicated in cardiac reperfusion injury.
The placebo-controlled, phase II proof-of-concept study in acute MI patients with large myocardial infarct undergoing percutaneous transluminal coronary angioplasty during percutaneous coronary intervention (PCI), is supported by the EU FP7 MitoCare project.
TRO40303 is administered as a single iv infusion prior to the reperfusion by angioplasty.
The phase I study demonstrated the safety, tolerability and pharmacokinetics of single escalating doses of TRO40303 as an intravenous infusion at different rates as compared to placebo.
The company is likely to announce the phase II results before the end of 2012.